CHEK
Price
$2.25
Change
+$1.66 (+281.36%)
Updated
Dec 23 closing price
64 days until earnings call
RSLS
Price
$4.26
Change
-$0.12 (-2.74%)
Updated
Dec 23 closing price
Ad is loading...

CHEK vs RSLS

Header iconCHEK vs RSLS Comparison
Open Charts CHEK vs RSLSBanner chart's image
Check-Cap
Price$2.25
Change+$1.66 (+281.36%)
Volume$40.09M
CapitalizationN/A
ReShape Lifesciences
Price$4.26
Change-$0.12 (-2.74%)
Volume$8.46K
CapitalizationN/A
CHEK vs RSLS Comparison Chart
Loading...
CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RSLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHEK vs. RSLS commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHEK is a Hold and RSLS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Dec 24, 2024
Stock price -- (CHEK: $2.25 vs. RSLS: $4.26)
Brand notoriety: CHEK and RSLS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CHEK: 4385% vs. RSLS: 9%
Market capitalization -- CHEK: $18.19M vs. RSLS: $4.33M
CHEK [@Medical Specialties] is valued at $18.19M. RSLS’s [@Medical Specialties] market capitalization is $4.33M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHEK’s FA Score shows that 1 FA rating(s) are green whileRSLS’s FA Score has 0 green FA rating(s).

  • CHEK’s FA Score: 1 green, 4 red.
  • RSLS’s FA Score: 0 green, 5 red.
According to our system of comparison, both CHEK and RSLS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHEK’s TA Score shows that 5 TA indicator(s) are bullish while RSLS’s TA Score has 3 bullish TA indicator(s).

  • CHEK’s TA Score: 5 bullish, 4 bearish.
  • RSLS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CHEK is a better buy in the short-term than RSLS.

Price Growth

CHEK (@Medical Specialties) experienced а +265.85% price change this week, while RSLS (@Medical Specialties) price change was -4.91% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.30%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was +2.47%.

Reported Earning Dates

CHEK is expected to report earnings on Feb 26, 2025.

RSLS is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Medical Specialties (-0.30% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHEK($18.2M) has a higher market cap than RSLS($4.33M). CHEK YTD gains are higher at: 8.173 vs. RSLS (-70.585). CHEK has higher annual earnings (EBITDA): -18.8M vs. RSLS (-36.72M). CHEK has more cash in the bank: 32.1M vs. RSLS (1.45M). CHEK has less debt than RSLS: CHEK (83K) vs RSLS (285K). RSLS has higher revenues than CHEK: RSLS (9.81M) vs CHEK (0).
CHEKRSLSCHEK / RSLS
Capitalization18.2M4.33M421%
EBITDA-18.8M-36.72M51%
Gain YTD8.173-70.585-12%
P/E RatioN/AN/A-
Revenue09.81M-
Total Cash32.1M1.45M2,215%
Total Debt83K285K29%
FUNDAMENTALS RATINGS
CHEK vs RSLS: Fundamental Ratings
CHEK
RSLS
OUTLOOK RATING
1..100
9968
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9692
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2875

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHEK's Valuation (28) in the Medical Specialties industry is in the same range as RSLS (37). This means that CHEK’s stock grew similarly to RSLS’s over the last 12 months.

CHEK's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RSLS (100). This means that CHEK’s stock grew similarly to RSLS’s over the last 12 months.

CHEK's SMR Rating (97) in the Medical Specialties industry is in the same range as RSLS (100). This means that CHEK’s stock grew similarly to RSLS’s over the last 12 months.

RSLS's Price Growth Rating (92) in the Medical Specialties industry is in the same range as CHEK (96). This means that RSLS’s stock grew similarly to CHEK’s over the last 12 months.

RSLS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as CHEK (100). This means that RSLS’s stock grew similarly to CHEK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHEKRSLS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 15 days ago
88%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RSLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CELZ2.170.10
+4.83%
Creative Medical Technology Holdings
MTX76.050.43
+0.57%
Minerals Technologies
TTEK39.83-0.37
-0.92%
Tetra Tech Inc
WMPN12.08-0.21
-1.71%
William Penn Bancorporation
OMER10.11-0.20
-1.94%
Omeros Corp

CHEK and

Correlation & Price change

A.I.dvisor tells us that CHEK and NVNO have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CHEK and NVNO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHEK
1D Price
Change %
CHEK100%
+281.36%
NVNO - CHEK
27%
Poorly correlated
+16.87%
IINN - CHEK
26%
Poorly correlated
+30.32%
TWST - CHEK
26%
Poorly correlated
+0.38%
RSLS - CHEK
26%
Poorly correlated
-2.74%
ICAD - CHEK
26%
Poorly correlated
-7.92%
More

RSLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RSLS has been loosely correlated with GENE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RSLS jumps, then GENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RSLS
1D Price
Change %
RSLS100%
-2.74%
GENE - RSLS
45%
Loosely correlated
N/A
HSCS - RSLS
35%
Loosely correlated
-3.39%
GMED - RSLS
31%
Poorly correlated
+0.57%
NARI - RSLS
30%
Poorly correlated
-3.99%
AZTA - RSLS
30%
Poorly correlated
-0.79%
More